2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2924

Determinants of Damage in an SLE Cohort: Real World Data

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2672

Determinants of Patient- Physician Discordance in Assessment of Global Disease Activity in Latinos with Rheumatoid Arthritis in the United States

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2501

Determining the Rate of Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis at Federally Qualified Outpatient Continuity Clinic – a Performance Improvement Project

Quality Measures and Quality of Care Poster Session

9:00AM-11:00AM: Abstract Number: 2445

Development and Usability Testing of an Ipad-Based Psycho-Educational Game for Children with Juvenile Idiopathic Arthritis and Their Parents

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

9:00AM-11:00AM: Abstract Number: 2679

Development and Validation of a HAQ-Derived Tool to Detect Muscle Mass Deficits in Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2632

Development and Validation of a Questionnaire Assessing the Fears and Beliefs of Patients Suffering from Chronic Rheumatic Diseases

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2952

Diagnosis of Primary Neuropsychiatric Systemic Lupus Erythematosus: Attribution Models Versus Physician Judgment

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2908

Diagnostic and Screening Accuracy of Spot Urinary Protein-Creatinine Ratio Compared to Protein Content in a 24 Hour-Urine Collection in Systemic Lupus Erythematosus: Systematic Review and Meta-Analysis

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2653

Diagnostic Value of the Prednisolone Test in Patients with Possible Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2929

Diet and Glucocorticoid Treatment in Patients with SLE

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2202

Different Patterns of Positivity for IgG Anti-Cardiolipin, Anti-Beta-2-Glycoprotein I and Anti-Domain I Antibodies within the First Year of Disease in 501 Patients with SLE – Associations with Different Clinical Outcomes

Antiphospholipid Syndrome: Clinical

9:00AM-11:00AM: Abstract Number: 2317

Different Rheumatoid Arthritis Disease Activity Measures Often Provide Discordant Results in Clinical Practice Populations

Health Services Research Poster III: Patient Reported Outcomes, Patient Education and Preferences

9:00AM-11:00AM: Abstract Number: 2646

Different Wording of the Patient Global Assessment Scale Leads to Different Rating of Disease Activity

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2949

Differential Serum Cytokine Profile in Patients with Systemic Lupus Erythematosus and Posterior Reversible Encephalopathy Syndrome: A Single-Center Study

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2945

Diffuse Alveolar Hemorrhage in SLE: Risk Factors, Response to Therapy, and Survival

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].